Population-based analysis of Actinobacillus pleuropneumoniae ApxIVA for use as a DIVA antigen.
Population-based analysis of Actinobacillus pleuropneumoniae ApxIVA for use as a DIVA antigen.
复制标题
DOI：
10.1016/j.vaccine.2010.04.113
复制
发表时间：
2010-07-12
期刊：
影响因子：
5.5
通讯作者：
Langford PR
中科院分区：
文献类型：
--
作者：
O'Neilla C;Jones SCP;Bossé JT;Watson CM;Williamson SM;Rycroft AN;Simon Kroll J;Hartley HM;Langford PR
APXIVA是胸膜肺炎放线杆菌的RTX毒素，是区分感染动物和接种动物（DIVA）的候选抗原。已知将ISApl 1插入apxIVA基因中会损害基于APXIVA的DIVA方法，因为在apxIVA基因中可能存在TGG至TGA突变。ISAp 11基因在349株中有63株（18.1%）阳性。来自英格兰和威尔士的胸膜肺炎分离株，包括血清型2、3、6-8和12。未发现ISApl 1插入apxIVA，仅2株血清型3分离株含有TGG → TGA突变。我们的结论是，基于ApxIVA的DIVA方法在英格兰和威尔士可能是可行的。
APXIVA is an RTX toxin of Actinobacillus pleuropneumoniae that is a candidate antigen to differentiate infected from vaccinated animals (DIVA). Insertion of ISApl1 into the apxIVA gene is known to compromise an APXIVA-based DIVA approach, as is potentially a TGG to TGA mutation in the apxIVA gene. ISApl1 was found in 63/349 (18.1%) A. pleuropneumoniae isolates from England and Wales including serovars 2, 3, 6–8 and 12. No ISApl1 insertions into apxIVA were found. Only two serovar 3 isolates contained the TGG to TGA mutation. We conclude that an ApxIVA-based DIVA approach would potentially be viable in England and Wales.